GNH USA

Europe — EMA

Meriofert Pfs

GNH USA supplies Meriofert Pfs (Luteinising Hormone, Follicle-Stimulating Hormone), a gonadotropin for infertility and assisted reproductive protocols.

Luteinising Hormone (Human), Follicle-Stimulating Hormone

Request sourcing

1
Pack/s

What is Luteinising Hormone (Human), Follicle-Stimulating Hormone?

Luteinising Hormone (Human), Follicle-Stimulating Hormone, the active ingredient in Meriofert Pfs, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It treats infertility related to anovulation, supports assisted reproductive technology protocols, and addresses hypogonadotropic hypogonadism.

GNH USA supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Luteinising Hormone (Human), Follicle-Stimulating Hormone used for?

Meriofert Pfs is a gonadotropin used in reproductive medicine to stimulate ovarian function in several clinical scenarios.

- Infertility due to anovulation: promotes follicular growth and induces ovulation. - Assisted reproductive technology (IVF) stimulation protocols: provides controlled ovarian hyperstimulation for egg retrieval. - Hypogonadotropic hypogonadism: replaces deficient LH and FSH to restore normal reproductive hormone balance.

What are the side effects of Luteinising Hormone (Human), Follicle-Stimulating Hormone?

Common Side Effects: - Injection site pain or erythema. - Headache. - Nausea. - Mild ovarian hyperstimulation syndrome.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome. - Thromboembolic events. - Anaphylactic or severe allergic reactions. - Multiple pregnancy. - Ovarian cyst rupture.

What precautions apply to Luteinising Hormone (Human), Follicle-Stimulating Hormone?

Meriofert Pfs requires careful clinical monitoring to minimise risks. - Monitor ovarian response: adjust dosing based on ultrasound and estradiol levels. - Assess OHSS risk: limit total gonadotropin exposure in high‑risk patients. - Evaluate for hypersensitivity: discontinue if severe allergic reaction occurs. - Use caution in patients with a history of thromboembolism: consider prophylactic measures. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Luteinising Hormone (Human), Follicle-Stimulating Hormone interact with?

Meriofert Pfs may interact with several agents used in fertility treatment.

Major Interactions (Avoid): - GnRH agonist therapy: can amplify ovarian response and increase OHSS risk. - hCG administration: synergistic effect may precipitate severe OHSS. - Estrogen‑containing contraceptives: may interfere with intended stimulation outcomes. - Anticoagulants: heightened bleeding risk with intramuscular injection.

Moderate Interactions (Monitor Closely): - Steroid medications: may modify ovarian response. - Thyroid hormone therapy: can affect overall hormone metabolism. - NSAIDs: may mask pain related to ovarian enlargement.

Frequently asked questions

What is Meriofert Pfs used for?+
Meriofert Pfs is an injectable gonadotropin used to treat infertility caused by anovulation, to support ovarian stimulation in assisted reproductive technologies such as in‑vitro fertilisation, and to replace deficient LH and FSH in patients with hypogonadotropic hypogonadism.
How does luteinising hormone and follicle‑stimulating hormone work in this product?+
The drug contains human LH and FSH which bind to their respective receptors on ovarian cells. This binding activates signaling pathways that promote follicle growth, estradiol production, ovulation, and luteal phase support, thereby restoring normal reproductive hormone activity.
What is the usual dose of Meriofert Pfs?+
The dose of Meriofert Pfs is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s specific condition, response to treatment, and monitoring results.
Is Meriofert Pfs safe to use during pregnancy or breastfeeding?+
Meriofert Pfs is intended for use before conception to achieve pregnancy. Its safety in established pregnancy or while breastfeeding has not been established, and it should only be used under specialist supervision when pregnancy is planned.
How do I order Meriofert Pfs from GNH USA?+
To order, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and required import documentation.
How does Meriofert Pfs compare with other fertility hormones?+
Meriofert Pfs combines both LH and FSH activity, whereas some alternatives contain only FSH. The dual activity can provide more physiologic stimulation for certain protocols, but the choice depends on the clinician’s assessment of the patient’s hormonal profile and treatment goals.
What are the storage and handling requirements for Meriofert Pfs?+
The product must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discoloured or particulate.
How is Meriofert Pfs administered?+
Meriofert Pfs is given by a healthcare professional as an intramuscular or subcutaneous injection. The injection site and technique are selected according to the prescribed regimen and patient comfort.
What are the most serious risks associated with Meriofert Pfs?+
The most serious risks include severe ovarian hyperstimulation syndrome, thromboembolic events, anaphylactic reactions, multiple pregnancy, and ovarian cyst rupture. Patients should be monitored closely for signs of these complications throughout treatment.
Who should not use Meriofert Pfs?+
Meriofert Pfs is contraindicated in individuals with known hypersensitivity to human LH or FSH, uncontrolled ovarian cysts, active thromboembolic disease, or those who are pregnant. It should also be used with caution in patients with severe ovarian failure where stimulation is unlikely to be effective.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Luteinising Hormone (Human), Follicle-Stimulating Hormone
Route
Intramuscular Use , Subcutaneous Use
Manufacturer
Ibsa Farmaceutici Italia
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU